Rhenium-188 (188Re) is a high energy beta-emitting radioisotope with a short 16.9 h
physical half-life, which has been shown to be a very attractive candidate for use in …

Summary Strontium-89 and samarium-153 are radioisotopes that are approved in the USA
and Europe for the palliation of pain from metastatic bone cancer, whereas rhenium-186 and …

Purpose Ra-dichloride is an alpha-emitting radiopharmaceutical used in the treatment of
bone metastases from castration-resistant prostate cancer. Image-based dosimetric studies …

Systemic therapy using bone-seeking radiopharmaceuticals has clear advantages for the
treatment of multisite metastatic pain. Evidence supporting the use of β-particle, electron …

Targeted radionuclide therapy (TRT) is a promising technique for cancer therapy. However,
in order to deliver the required dose to the tumor, minimize potential toxicity in normal …

Aim The surface bone-seeking radiopharmaceuticals 188 Re-HEDP, 186 Re-HEDP and 153
Sm-EDTMP, and the volume seeker 89 Sr were investigated to determine the efficacy and …

Purpose The present review article aims to provide an overview of the available
radionuclides for palliative treatment of bone metastases beyond 89 Sr and 153 Sm. In …

Rhenium-188 is one of the most readily available generator derived and useful
radionuclides for therapy emitting β-particles (2.12 MeV, 71.1% and 1.965 MeV, 25.6%) and …

Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known
concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone …

Rhenium-188 (Re-188) is a high energy-emitting radioisotope obtained from the tungsten-
188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of …